[Leukemia].

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Leukemia originates from genetically altered hematopoietic stem/progenitor cells.
• Current leukemia therapy relies on risk stratification, but survival rates remain suboptimal (40% 5-year).
• Leukemia is heterogeneous, with subtypes exhibiting distinct genetic aberrations and prognoses.

Purpose of the Study:

• To explore advanced genetic profiling methods for improved leukemia risk stratification.
• To enhance molecular subtyping and prognostic accuracy in leukemia, particularly acute myeloid leukemia (AML).

Main Methods:

• Conventional cytogenetic analysis for chromosome aberrations.
• Identification of specific gene mutations (e.g., NPM1, CEBPA, FLT3) in AML.
• Array-based gene expression analysis and whole exome/transcriptome sequencing.

Main Results:

• Normal karyotype in AML often indicates diverse subtypes with varied prognoses.
• Driver mutations significantly influence leukemia prognosis.
• Advanced genetic profiling can identify a comprehensive spectrum of aberrations and mutations.

Conclusions:

• Genetic profiling provides more accurate molecular subtyping and risk stratification in leukemia.
• Enhanced precision in risk stratification can lead to more tailored and effective treatment strategies.
• Next-generation sequencing methods are crucial for understanding leukemia complexity and improving patient outcomes.